{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:56:33Z","timestamp":1769752593431,"version":"3.49.0"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40266-025-01269-3","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:30:02Z","timestamp":1765812602000},"page":"49-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Management of Glucocorticoid-Induced Osteoporosis with a Focus on Older Adults: A Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-1906","authenticated-orcid":false,"given":"Elena","family":"Tsourdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1650","authenticated-orcid":false,"given":"Ulrike","family":"Baschant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-6799","authenticated-orcid":false,"given":"Martina","family":"Rauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8254-9333","authenticated-orcid":false,"given":"Hanna","family":"Taipaleenm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-1588","authenticated-orcid":false,"given":"Elizabeth M.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"11","key":"1269_CR1","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/rheumatology\/ker017","volume":"50","author":"L Fardet","year":"2011","unstructured":"Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011;50(11):1982\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1269_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1530\/EJE-19-0305","volume":"181","author":"K Laugesen","year":"2019","unstructured":"Laugesen K, et al. Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. Eur J Endocrinol. 2019;181(3):267\u201373.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1269_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/acr.21796","volume":"65","author":"RA Overman","year":"2013","unstructured":"Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013;65(2):294\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1269_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","volume":"93","author":"TP van Staa","year":"2000","unstructured":"van Staa TP, et al. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105\u201311.","journal-title":"QJM"},{"issue":"6","key":"1269_CR5","doi-asserted-by":"publisher","first-page":"C23","DOI":"10.1530\/EJE-19-0555","volume":"181","author":"OC Meijer","year":"2019","unstructured":"Meijer OC, Pereira AM. Three percent annually on systemic glucocorticoids: facts, worries and perspectives. Eur J Endocrinol. 2019;181(6):C23\u20138.","journal-title":"Eur J Endocrinol"},{"issue":"26","key":"1269_CR6","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","volume":"379","author":"L Buckley","year":"2018","unstructured":"Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018;379(26):2547\u201356.","journal-title":"N Engl J Med"},{"issue":"10","key":"1269_CR7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"Canalis E, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319\u201328.","journal-title":"Osteoporos Int"},{"key":"1269_CR8","doi-asserted-by":"crossref","unstructured":"Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003;32(1):135\u201357, vii.","DOI":"10.1016\/S0889-8529(02)00064-6"},{"key":"1269_CR9","doi-asserted-by":"crossref","unstructured":"Kanis JA, et al. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2007;11(7):iii\u2013iv, ix\u2013xi, 1\u2013231.","DOI":"10.3310\/hta11070"},{"issue":"10","key":"1269_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP van Staa","year":"2002","unstructured":"van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777\u201387.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1269_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","volume":"39","author":"A Angeli","year":"2006","unstructured":"Angeli A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253\u20139.","journal-title":"Bone"},{"issue":"4","key":"1269_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00198-003-1548-3","volume":"15","author":"M Steinbuch","year":"2004","unstructured":"Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004;15(4):323\u20138.","journal-title":"Osteoporos Int"},{"issue":"5","key":"1269_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00198-024-07023-6","volume":"35","author":"M Iki","year":"2024","unstructured":"Iki M, et al. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan. Osteoporos Int. 2024;35(5):805\u201318.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1269_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105604","volume":"90","author":"AD Anastasilakis","year":"2023","unstructured":"Anastasilakis AD, et al. Risk and management of osteoporosis due to inhaled, epidural, intra-articular or topical glucocorticoids. Jt Bone Spine. 2023;90(6):105604.","journal-title":"Jt Bone Spine"},{"issue":"2","key":"1269_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/jbmr\/zjae162","volume":"40","author":"H Yun","year":"2025","unstructured":"Yun H, et al. Epidural steroid injections and fracture incidence among older individuals with radiculopathy. J Bone Miner Res. 2025;40(2):176\u201383.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1269_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000014","volume":"1","author":"K Briot","year":"2015","unstructured":"Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open. 2015;1(1):e000014.","journal-title":"RMD Open"},{"issue":"3","key":"1269_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00223-006-0019-1","volume":"79","author":"TP van Staa","year":"2006","unstructured":"van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79(3):129\u201337.","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"1269_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/BOR.0000000000000608","volume":"31","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG. Glucocorticoid-induced osteoporosis update. Curr Opin Rheumatol. 2019;31(4):388\u201393.","journal-title":"Curr Opin Rheumatol"},{"issue":"18","key":"1269_CR19","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799\u2013809.","journal-title":"N Engl J Med"},{"issue":"7","key":"1269_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s001980070075","volume":"11","author":"JA Cauley","year":"2000","unstructured":"Cauley JA, et al. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11(7):556\u201361.","journal-title":"Osteoporos Int"},{"key":"1269_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2474-10-135","volume":"10","author":"I Hallberg","year":"2009","unstructured":"Hallberg I, et al. Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. BMC Musculoskelet Disord. 2009;10:135.","journal-title":"BMC Musculoskelet Disord"},{"issue":"9156","key":"1269_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878\u201382.","journal-title":"Lancet"},{"issue":"9","key":"1269_CR23","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/jbmr.2301","volume":"29","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, et al. The osteoporosis treatment gap. J Bone Miner Res. 2014;29(9):1926\u20138.","journal-title":"J Bone Miner Res"},{"key":"1269_CR24","unstructured":"Nederland Z. Zinnige Zorg - Verbetersignalement Osteoporose. 2020."},{"issue":"11","key":"1269_CR25","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","volume":"21","author":"I Imaz","year":"2010","unstructured":"Imaz I, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21(11):1943\u201351.","journal-title":"Osteoporos Int"},{"issue":"9540","key":"1269_CR26","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(06)69394-X","volume":"368","author":"JE Compston","year":"2006","unstructured":"Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet. 2006;368(9540):973\u20134.","journal-title":"Lancet"},{"issue":"12","key":"1269_CR27","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, et al. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis. J Bone Miner Res. 2015;30(12):2179\u201387.","journal-title":"J Bone Miner Res"},{"key":"1269_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2024.101750","volume":"20","author":"AE Smit","year":"2024","unstructured":"Smit AE, Meijer OC, Winter EM. The multi-faceted nature of age-associated osteoporosis. Bone Rep. 2024;20:101750.","journal-title":"Bone Rep"},{"issue":"10","key":"1269_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10504","volume":"5","author":"EM Winter","year":"2021","unstructured":"Winter EM, et al. Chronobiology and chronotherapy of osteoporosis. JBMR Plus. 2021;5(10):e10504.","journal-title":"JBMR Plus"},{"issue":"6","key":"1269_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1359\/jbmr.2002.17.6.979","volume":"17","author":"MS Cooper","year":"2002","unstructured":"Cooper MS, et al. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res. 2002;17(6):979\u201386.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1269_CR31","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1210\/jcem-72-2-382","volume":"72","author":"MF Prummel","year":"1991","unstructured":"Prummel MF, et al. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab. 1991;72(2):382\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1269_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1359\/JBMR.051103","volume":"21","author":"NE Lane","year":"2006","unstructured":"Lane NE, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res. 2006;21(3):466\u201376.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1269_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2010.05.005","volume":"11","author":"A Rauch","year":"2010","unstructured":"Rauch A, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11(6):517\u201331.","journal-title":"Cell Metab"},{"issue":"5","key":"1269_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/jbmr.5650110516","volume":"11","author":"D Chappard","year":"1996","unstructured":"Chappard D, et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res. 1996;11(5):676\u201385.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1269_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/jbmr.5650040202","volume":"4","author":"DW Dempster","year":"1989","unstructured":"Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989;4(2):137\u201341.","journal-title":"J Bone Miner Res"},{"key":"1269_CR36","doi-asserted-by":"publisher","first-page":"30186","DOI":"10.1038\/srep30186","volume":"6","author":"B Sui","year":"2016","unstructured":"Sui B, et al. Mesenchymal progenitors in osteopenias of diverse pathologies: differential characteristics in the common shift from osteoblastogenesis to adipogenesis. Sci Rep. 2016;6:30186.","journal-title":"Sci Rep"},{"issue":"6","key":"1269_CR37","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s00223-009-9303-1","volume":"85","author":"W Mak","year":"2009","unstructured":"Mak W, et al. Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int. 2009;85(6):538\u201345.","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1269_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbrc.2008.12.035","volume":"379","author":"K Hayashi","year":"2009","unstructured":"Hayashi K, et al. BMP\/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2009;379(2):261\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"1269_CR39","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/jbmr.3702","volume":"34","author":"J Colditz","year":"2019","unstructured":"Colditz J, et al. Osteogenic Dkk1 mediates glucocorticoid-induced but not arthritis-induced bone loss. J Bone Miner Res. 2019;34(7):1314\u201323.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1269_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.stem.2017.02.009","volume":"20","author":"TH Ambrosi","year":"2017","unstructured":"Ambrosi TH, et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell. 2017;20(6):771-84.e6.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"1269_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11357-008-9069-9","volume":"30","author":"M Rauner","year":"2008","unstructured":"Rauner M, Sipos W, Pietschmann P. Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. Age. 2008;30(4):273\u201382.","journal-title":"Age"},{"issue":"2","key":"1269_CR42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1172\/JCI2799","volume":"102","author":"RS Weinstein","year":"1998","unstructured":"Weinstein RS, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274\u201382.","journal-title":"J Clin Invest"},{"issue":"4","key":"1269_CR43","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/en.2003-0990","volume":"145","author":"CA O'Brien","year":"2004","unstructured":"O\u2019Brien CA, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835\u201341.","journal-title":"Endocrinology"},{"key":"1269_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2019.01.025","volume":"122","author":"LM Tiede-Lewis","year":"2019","unstructured":"Tiede-Lewis LM, Dallas SL. Changes in the osteocyte lacunocanalicular network with aging. Bone. 2019;122:101\u201313.","journal-title":"Bone"},{"issue":"2","key":"1269_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1474-9726.2009.00545.x","volume":"9","author":"RS Weinstein","year":"2010","unstructured":"Weinstein RS, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010;9(2):147\u201361.","journal-title":"Aging Cell"},{"key":"1269_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2018.05.025","volume":"114","author":"P Yang","year":"2018","unstructured":"Yang P, et al. Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice. Bone. 2018;114:1\u201313.","journal-title":"Bone"},{"issue":"6","key":"1269_CR47","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bone.2003.08.002","volume":"33","author":"T Pufe","year":"2003","unstructured":"Pufe T, et al. The role of vascular endothelial growth factor in glucocorticoid-induced bone loss: evaluation in a minipig model. Bone. 2003;33(6):869\u201376.","journal-title":"Bone"},{"key":"1269_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.835720","volume":"13","author":"M Gado","year":"2022","unstructured":"Gado M, et al. Bad to the bone: the effects of therapeutic glucocorticoids on osteoblasts and osteocytes. Front Endocrinol (Lausanne). 2022;13:835720.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"1269_CR49","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","volume":"140","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140(10):4382\u20139.","journal-title":"Endocrinology"},{"issue":"3","key":"1269_CR50","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1210\/endo.139.3.5778","volume":"139","author":"J Rubin","year":"1998","unstructured":"Rubin J, et al. Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology. 1998;139(3):1006\u201312.","journal-title":"Endocrinology"},{"issue":"5","key":"1269_CR51","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1530\/eje.1.02147","volume":"154","author":"A Dovio","year":"2006","unstructured":"Dovio A, et al. High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol. 2006;154(5):745\u201351.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1269_CR52","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1210\/en.2006-0459","volume":"147","author":"D Jia","year":"2006","unstructured":"Jia D, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006;147(12):5592\u20139.","journal-title":"Endocrinology"},{"issue":"8","key":"1269_CR53","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/jcb.24792","volume":"115","author":"PL Chung","year":"2014","unstructured":"Chung PL, et al. Effect of age on regulation of human osteoclast differentiation. J Cell Biochem. 2014;115(8):1412\u20139.","journal-title":"J Cell Biochem"},{"issue":"11","key":"1269_CR54","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/jbmr.2892","volume":"31","author":"JN Farr","year":"2016","unstructured":"Farr JN, et al. Identification of senescent cells in the bone microenvironment. J Bone Miner Res. 2016;31(11):1920\u20139.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1269_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22131-1","volume":"12","author":"X Liu","year":"2021","unstructured":"Liu X, et al. Osteoclasts protect bone blood vessels against senescence through the angiogenin\/plexin-B2 axis. Nat Commun. 2021;12(1):1832.","journal-title":"Nat Commun"},{"issue":"1","key":"1269_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41392-021-00528-0","volume":"6","author":"T Wang","year":"2021","unstructured":"Wang T, et al. Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1 axis. Signal Transduct Target Ther. 2021;6(1):143.","journal-title":"Signal Transduct Target Ther"},{"key":"1269_CR57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbrc.2022.02.112","volume":"602","author":"F Sun","year":"2022","unstructured":"Sun F, et al. Dexamethasone induces ferroptosis via P53\/SLC7A11\/GPX4 pathway in glucocorticoid-induced osteonecrosis of the femoral head. Biochem Biophys Res Commun. 2022;602:149\u201355.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1269_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41413-023-00247-y","volume":"11","author":"Q Ru","year":"2023","unstructured":"Ru Q, et al. Fighting age-related orthopedic diseases: focusing on ferroptosis. Bone Res. 2023;11(1):12.","journal-title":"Bone Res"},{"key":"1269_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2014.47","volume":"3","author":"S Thiele","year":"2014","unstructured":"Thiele S, et al. Instructions for producing a mouse model of glucocorticoid-induced osteoporosis. BoneKEy Rep. 2014;3:552.","journal-title":"BoneKEy Rep"},{"issue":"4","key":"1269_CR60","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","volume":"17","author":"G Mazziotti","year":"2006","unstructured":"Mazziotti G, et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006;17(4):144\u20139.","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"1269_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1530\/eje.1.01841","volume":"152","author":"S Bonadonna","year":"2005","unstructured":"Bonadonna S, et al. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol. 2005;152(2):199\u2013205.","journal-title":"Eur J Endocrinol"},{"key":"1269_CR62","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000061083","volume":"30","author":"F Manelli","year":"2002","unstructured":"Manelli F, et al. Growth hormone in glucocorticoid-induced osteoporosis. Front Horm Res. 2002;30:174\u201383.","journal-title":"Front Horm Res"},{"issue":"1","key":"1269_CR63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00198-005-1923-3","volume":"17","author":"K Natsui","year":"2006","unstructured":"Natsui K, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006;17(1):105\u20138.","journal-title":"Osteoporos Int"},{"issue":"1","key":"1269_CR64","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1210\/en.2006-0539","volume":"148","author":"H Gilson","year":"2007","unstructured":"Gilson H, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology. 2007;148(1):452\u201360.","journal-title":"Endocrinology"},{"issue":"1","key":"1269_CR65","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1152\/physrev.00061.2017","volume":"99","author":"L Larsson","year":"2019","unstructured":"Larsson L, et al. Sarcopenia: aging-related loss of muscle mass and function. Physiol Rev. 2019;99(1):427\u2013511.","journal-title":"Physiol Rev"},{"issue":"1","key":"1269_CR66","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1096\/fj.201901929R","volume":"34","author":"M Schilperoort","year":"2020","unstructured":"Schilperoort M, et al. Circadian disruption by shifting the light-dark cycle negatively affects bone health in mice. FASEB J. 2020;34(1):1052\u201364.","journal-title":"FASEB J"},{"issue":"4","key":"1269_CR67","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00198-008-0729-5","volume":"20","author":"D Feskanich","year":"2009","unstructured":"Feskanich D, Hankinson SE, Schernhammer ES. Nightshift work and fracture risk: the Nurses\u2019 Health Study. Osteoporos Int. 2009;20(4):537\u201342.","journal-title":"Osteoporos Int"},{"issue":"4","key":"1269_CR68","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jocd.2010.07.004","volume":"13","author":"I Quevedo","year":"2010","unstructured":"Quevedo I, Zuniga AM. Low bone mineral density in rotating-shift workers. J Clin Densitom. 2010;13(4):467\u20139.","journal-title":"J Clin Densitom"},{"issue":"10","key":"1269_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13474","volume":"20","author":"M Schilperoort","year":"2021","unstructured":"Schilperoort M, et al. Loss of glucocorticoid rhythm induces an osteoporotic phenotype in female mice. Aging Cell. 2021;20(10):e13474.","journal-title":"Aging Cell"},{"issue":"14","key":"1269_CR70","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.18632\/aging.204192","volume":"14","author":"AE Smit","year":"2022","unstructured":"Smit AE, Schilperoort M, Winter EM. Restoring rhythm to prevent age-related fractures. Aging Albany NY. 2022;14(14):5617\u20139.","journal-title":"Aging Albany NY"},{"issue":"4","key":"1269_CR71","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00774-022-01325-7","volume":"40","author":"S Soen","year":"2022","unstructured":"Soen S, et al. Fracture risk associated with glucocorticoid-induced osteoporosis in Japan. J Bone Miner Metab. 2022;40(4):636\u201347.","journal-title":"J Bone Miner Metab"},{"issue":"6","key":"1269_CR72","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1359\/JBMR.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893\u20139.","journal-title":"J Bone Miner Res"},{"key":"1269_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101608","volume":"77","author":"J Cui","year":"2022","unstructured":"Cui J, et al. Osteocytes in bone aging: advances, challenges, and future perspectives. Ageing Res Rev. 2022;77:101608.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"1269_CR74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11914-016-0297-0","volume":"14","author":"RL Jilka","year":"2016","unstructured":"Jilka RL, O\u2019Brien CA. The role of osteocytes in age-related bone loss. Curr Osteoporos Rep. 2016;14(1):16\u201325.","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"1269_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00223-023-01100-4","volume":"113","author":"CL Fang","year":"2023","unstructured":"Fang CL, Liu B, Wan M. \u201cBone-SASP\u201d in skeletal aging. Calcif Tissue Int. 2023;113(1):68\u201382.","journal-title":"Calcif Tissue Int"},{"key":"1269_CR76","doi-asserted-by":"publisher","first-page":"16041","DOI":"10.1038\/boneres.2016.41","volume":"4","author":"V Veldurthy","year":"2016","unstructured":"Veldurthy V, et al. Vitamin D, calcium homeostasis and aging. Bone Res. 2016;4:16041.","journal-title":"Bone Res"},{"issue":"1","key":"1269_CR77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61\u201398.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1269_CR78","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000183237","volume":"37","author":"PM Rosman","year":"1984","unstructured":"Rosman PM, et al. Cortisol binding in uremic plasma. I. Absence of abnormal cortisol binding to cortisol binding to corticosteroid-binding globulin. Nephron. 1984;37(3):160\u20135.","journal-title":"Nephron"},{"issue":"4","key":"1269_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000183254","volume":"37","author":"PM Rosman","year":"1984","unstructured":"Rosman PM, et al. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin. Nephron. 1984;37(4):229\u201331.","journal-title":"Nephron"},{"issue":"6","key":"1269_CR80","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/0092-8674(90)90397-W","volume":"62","author":"R Schule","year":"1990","unstructured":"Schule R, et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 1990;62(6):1217\u201326.","journal-title":"Cell"},{"issue":"6","key":"1269_CR81","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/0092-8674(90)90396-V","volume":"62","author":"HF Yang-Yen","year":"1990","unstructured":"Yang-Yen HF, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell. 1990;62(6):1205\u201315.","journal-title":"Cell"},{"issue":"6","key":"1269_CR82","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/0092-8674(90)90395-U","volume":"62","author":"C Jonat","year":"1990","unstructured":"Jonat C, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos\/Jun) activity by glucocorticoid hormone. Cell. 1990;62(6):1189\u2013204.","journal-title":"Cell"},{"issue":"2","key":"1269_CR83","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.immuni.2017.07.012","volume":"47","author":"KS Oh","year":"2017","unstructured":"Oh KS, et al. Anti-inflammatory chromatinscape suggests alternative mechanisms of glucocorticoid receptor action. Immunity. 2017;47(2):298-309.e5.","journal-title":"Immunity"},{"issue":"5959","key":"1269_CR84","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/308513a0","volume":"308","author":"M Karin","year":"1984","unstructured":"Karin M, et al. Characterization of DNA sequences through which cadmium and glucocorticoid hormones induce human metallothionein-IIA gene. Nature. 1984;308(5959):513\u20139.","journal-title":"Nature"},{"issue":"1-2","key":"1269_CR85","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.mce.2007.05.014","volume":"275","author":"H Schacke","year":"2007","unstructured":"Schacke H, et al. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007;275(1\u20132):109\u201317.","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"1269_CR86","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1515\/hsz-2015-0106","volume":"396","author":"S Hubner","year":"2015","unstructured":"Hubner S, et al. The glucocorticoid receptor in inflammatory processes: transrepression is not enough. Biol Chem. 2015;396(11):1223\u201331.","journal-title":"Biol Chem"},{"issue":"6","key":"1269_CR87","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0039-128X(01)00171-4","volume":"67","author":"F Buttgereit","year":"2002","unstructured":"Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002;67(6):529\u201334.","journal-title":"Steroids"},{"key":"1269_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12364","volume":"1318","author":"C Strehl","year":"2014","unstructured":"Strehl C, Buttgereit F. Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. Ann N Y Acad Sci. 2014;1318:1\u20136.","journal-title":"Ann N Y Acad Sci"},{"key":"1269_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2016.08.019","volume":"111","author":"M Shaqura","year":"2016","unstructured":"Shaqura M, et al. Membrane-bound glucocorticoid receptors on distinct nociceptive neurons as potential targets for pain control through rapid non-genomic effects. Neuropharmacology. 2016;111:1\u201313.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1269_CR90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41422-024-01016-0","volume":"35","author":"W Fu","year":"2025","unstructured":"Fu W, et al. Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss. Cell Res. 2025;35(1):23\u201344.","journal-title":"Cell Res"},{"issue":"3","key":"1269_CR91","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S8756-3282(00)00344-6","volume":"27","author":"MS Cooper","year":"2000","unstructured":"Cooper MS, et al. Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone. 2000;27(3):375\u201381.","journal-title":"Bone"},{"issue":"1","key":"1269_CR92","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13075-019-1972-1","volume":"21","author":"CG Fenton","year":"2019","unstructured":"Fenton CG, et al. 11Beta-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy. Arthritis Res Ther. 2019;21(1):188.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1269_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1962-3","volume":"21","author":"CG Fenton","year":"2019","unstructured":"Fenton CG, et al. Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis. Arthritis Res Ther. 2019;21(1):182.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1269_CR94","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1210\/er.2018-00097","volume":"39","author":"RS Hardy","year":"2018","unstructured":"Hardy RS, et al. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev. 2018;39(5):519\u201348.","journal-title":"Endocr Rev"},{"issue":"4","key":"1269_CR95","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/clpt.1988.43","volume":"43","author":"AE Stuck","year":"1988","unstructured":"Stuck AE, Frey BM, Frey FJ. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin Pharmacol Ther. 1988;43(4):354\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1269_CR96","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1532-5415.1994.tb06219.x","volume":"42","author":"KM Tornatore","year":"1994","unstructured":"Tornatore KM, et al. Pharmacokinetics of methylprednisolone in elderly and young healthy males. J Am Geriatr Soc. 1994;42(10):1118\u201322.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1269_CR97","doi-asserted-by":"publisher","first-page":"207.e1","DOI":"10.1016\/j.neurobiolaging.2010.09.010","volume":"33","author":"AM MacLullich","year":"2012","unstructured":"MacLullich AM, et al. 11Beta-hydroxysteroid dehydrogenase type 1, brain atrophy and cognitive decline. Neurobiol Aging. 2012;33(1):207.e1-8.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1269_CR98","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0399","volume":"261","author":"E Macfarlane","year":"2024","unstructured":"Macfarlane E, Zhou H, Seibel MJ. The glucocorticoid receptor in skeletal health and disease: insights from targeted knockout mice. J Endocrinol. 2024;261(2):e230399.","journal-title":"J Endocrinol"},{"issue":"11","key":"1269_CR99","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1002\/art.23954","volume":"58","author":"W Yao","year":"2008","unstructured":"Yao W, et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 2008;58(11):3485\u201397.","journal-title":"Arthritis Rheum"},{"key":"1269_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118033","volume":"257","author":"M Eskandarynasab","year":"2020","unstructured":"Eskandarynasab M, et al. Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: a potential combination therapy with alendronate. Life Sci. 2020;257:118033.","journal-title":"Life Sci"},{"issue":"11","key":"1269_CR101","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00296-011-2074-9","volume":"32","author":"KJ Zhang","year":"2012","unstructured":"Zhang KJ, et al. Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits. Rheumatol Int. 2012;32(11):3405\u201311.","journal-title":"Rheumatol Int"},{"issue":"9","key":"1269_CR102","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/BF03350811","volume":"30","author":"L Dalle Carbonare","year":"2007","unstructured":"Dalle Carbonare L, et al. Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. J Endocrinol Invest. 2007;30(9):739\u201346.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1269_CR103","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3181\/00379727-217-44218","volume":"217","author":"SJ Wimalawansa","year":"1998","unstructured":"Wimalawansa SJ, Simmons DJ. Prevention of corticosteroid-induced bone loss with alendronate. Proc Soc Exp Biol Med. 1998;217(2):162\u20137.","journal-title":"Proc Soc Exp Biol Med"},{"issue":"3","key":"1269_CR104","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1359\/JBMR.041233","volume":"20","author":"S Sivagurunathan","year":"2005","unstructured":"Sivagurunathan S, et al. Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res. 2005;20(3):390\u20138.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1269_CR105","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1210\/en.2010-0456","volume":"152","author":"M Rauner","year":"2011","unstructured":"Rauner M, et al. Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. Endocrinology. 2011;152(1):103\u201312.","journal-title":"Endocrinology"},{"issue":"5","key":"1269_CR106","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/art.24445","volume":"60","author":"LC Hofbauer","year":"2009","unstructured":"Hofbauer LC, et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum. 2009;60(5):1427\u201337.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1269_CR107","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1210\/en.2011-0170","volume":"152","author":"RS Weinstein","year":"2011","unstructured":"Weinstein RS, et al. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology. 2011;152(9):3323\u201331.","journal-title":"Endocrinology"},{"issue":"7","key":"1269_CR108","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1530\/EC-19-0104","volume":"8","author":"S Thiele","year":"2019","unstructured":"Thiele S, et al. Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. Endocrine Connect. 2019;8(7):923\u201334.","journal-title":"Endocrine Connect"},{"issue":"1","key":"1269_CR109","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbrc.2004.04.025","volume":"318","author":"K Ohnaka","year":"2004","unstructured":"Ohnaka K, et al. Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun. 2004;318(1):259\u201364.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"1269_CR110","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/jbmr.2988","volume":"31","author":"U Baschant","year":"2016","unstructured":"Baschant U, et al. Sclerostin blockade: a dual mode of action after all? J Bone Miner Res. 2016;31(10):1787\u201390.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1269_CR111","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jbmr.2869","volume":"31","author":"AY Sato","year":"2016","unstructured":"Sato AY, et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of SOST\/Sclerostin. J Bone Miner Res. 2016;31(10):1791\u2013802.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1269_CR112","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1210\/en.2013-1915","volume":"154","author":"R Kuriwaka-Kido","year":"2013","unstructured":"Kuriwaka-Kido R, et al. Parathyroid hormone (1\u201334) counteracts the suppression of interleukin-11 expression by glucocorticoid in murine osteoblasts: a possible mechanism for stimulating osteoblast differentiation against glucocorticoid excess. Endocrinology. 2013;154(3):1156\u201367.","journal-title":"Endocrinology"},{"key":"1269_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2025.111436","volume":"410","author":"J Fan","year":"2025","unstructured":"Fan J, et al. Protosappanin B activates the Wnt pathway to protect against glucocorticoid-induced osteoblast inhibition and enhance bone formation. Chem Biol Interact. 2025;410:111436.","journal-title":"Chem Biol Interact"},{"issue":"14","key":"1269_CR114","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.175089","volume":"9","author":"S Pal China","year":"2024","unstructured":"Pal China S, et al. Protein kinase G2 activation restores Wnt signaling and bone mass in glucocorticoid-induced osteoporosis in mice. JCI Insight. 2024;9(14):e175089.","journal-title":"JCI Insight"},{"key":"1269_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112635","volume":"133","author":"T Wang","year":"2022","unstructured":"Wang T, et al. Pulsed electromagnetic fields attenuate glucocorticoid-induced bone loss by targeting senescent LepR(+) bone marrow mesenchymal stromal cells. Biomater Adv. 2022;133:112635.","journal-title":"Biomater Adv"},{"key":"1269_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2023.105080","volume":"114","author":"N Cao","year":"2023","unstructured":"Cao N, et al. Cmpk2 regulates mitochondrial function in glucocorticoid-induced osteoblast senescence and affects glucocorticoid-inhibited osteoblast differentiation. Arch Gerontol Geriatr. 2023;114:105080.","journal-title":"Arch Gerontol Geriatr"},{"key":"1269_CR117","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.freeradbiomed.2022.08.007","volume":"190","author":"D Rai","year":"2022","unstructured":"Rai D, et al. A novel BMP2 secretagogue ameliorates glucocorticoid induced oxidative stress in osteoblasts by activating NRF2 dependent survival while promoting Wnt\/beta-catenin mediated osteogenesis. Free Radic Biol Med. 2022;190:124\u201347.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"1269_CR118","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13018-024-04775-z","volume":"19","author":"W Wang","year":"2024","unstructured":"Wang W, et al. Astaxanthin-mediated Nrf2 activation ameliorates glucocorticoid-induced oxidative stress and mitochondrial dysfunction and impaired bone formation of glucocorticoid-induced osteonecrosis of the femoral head in rats. J Orthop Surg Res. 2024;19(1):294.","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"1269_CR119","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00198-014-2883-2","volume":"26","author":"S Silverman","year":"2015","unstructured":"Silverman S, et al. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. 2015;26(1):419\u201320.","journal-title":"Osteoporos Int"},{"issue":"8","key":"1269_CR120","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/art.21194","volume":"52","author":"JR Curtis","year":"2005","unstructured":"Curtis JR, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 2005;52(8):2485\u201394.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1269_CR121","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1007\/s00198-005-2016-z","volume":"16","author":"AC Feldstein","year":"2005","unstructured":"Feldstein AC, et al. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int. 2005;16(12):2168\u201374.","journal-title":"Osteoporos Int"},{"issue":"10","key":"1269_CR122","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3899\/jrheum.130041","volume":"40","author":"SR Majumdar","year":"2013","unstructured":"Majumdar SR, et al. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol. 2013;40(10):1736\u201341.","journal-title":"J Rheumatol"},{"issue":"12","key":"1269_CR123","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP van Staa","year":"2000","unstructured":"van Staa TP, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"1269_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.908727","volume":"13","author":"MR Laurent","year":"2022","unstructured":"Laurent MR, et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the Belgian Bone Club. Front Endocrinol (Lausanne). 2022;13:908727.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1269_CR125","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1093\/ejendo\/lvad029","volume":"188","author":"JE Compston","year":"2023","unstructured":"Compston JE. Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis. Eur J Endocrinol. 2023;188(3):R46-55.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1269_CR126","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkad019","volume":"7","author":"S Kast","year":"2023","unstructured":"Kast S, et al. Exercise effects on glucocorticoid-induced bone loss in adults: a systematic review and meta-analysis. Rheumatol Adv Pract. 2023;7(1):rkad019.","journal-title":"Rheumatol Adv Pract"},{"issue":"6","key":"1269_CR127","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa TP, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993\u20131000.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1269_CR128","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1210\/jcem-52-1-111","volume":"52","author":"TJ Hahn","year":"1981","unstructured":"Hahn TJ, Halstead LR, Baran DT. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981;52(1):111\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1269_CR129","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0026-0495(83)90221-4","volume":"32","author":"Y Suzuki","year":"1983","unstructured":"Suzuki Y, et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983;32(2):151\u20136.","journal-title":"Metabolism"},{"issue":"24","key":"1269_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/nu15245066","volume":"15","author":"H Vatanparast","year":"2023","unstructured":"Vatanparast H, et al. Comparative analysis of dietary and supplemental intake of calcium and vitamin D among Canadian older adults with heart disease and\/or osteoporosis in 2004 and 2015. Nutrients. 2023;15(24):506.","journal-title":"Nutrients"},{"issue":"12","key":"1269_CR131","doi-asserted-by":"publisher","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","volume":"125","author":"LM Buckley","year":"1996","unstructured":"Buckley LM, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;125(12):961\u20138.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1269_CR132","first-page":"995","volume":"23","author":"JD Adachi","year":"1996","unstructured":"Adachi JD, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol. 1996;23(6):995\u20131000.","journal-title":"J Rheumatol"},{"issue":"2","key":"1269_CR133","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10067-020-05294-y","volume":"40","author":"J Deng","year":"2021","unstructured":"Deng J, et al. The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis. Clin Rheumatol. 2021;40(2):725\u201334.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1269_CR134","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00198-003-1570-5","volume":"15","author":"F Richy","year":"2004","unstructured":"Richy F, et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004;15(4):301\u201310.","journal-title":"Osteoporos Int"},{"issue":"8","key":"1269_CR135","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00198-004-1614-5","volume":"15","author":"RN de Nijs","year":"2004","unstructured":"de Nijs RN, et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int. 2004;15(8):589\u2013602.","journal-title":"Osteoporos Int"},{"issue":"4","key":"1269_CR136","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz212","volume":"105","author":"EO Billington","year":"2020","unstructured":"Billington EO, et al. Safety of high-dose vitamin D supplementation: secondary analysis of a randomized controlled trial. J Clin Endocrinol Metab. 2020;105(4):dgz212.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1269_CR137","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257\u201376.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1269_CR138","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","volume":"191","author":"J Paccou","year":"2024","unstructured":"Paccou J, et al. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. Eur J Endocrinol. 2024;191(6):G1-17.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1269_CR139","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/acr.25240","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405\u201319.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"1269_CR140","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s40265-019-01145-6","volume":"79","author":"HG Raterman","year":"2019","unstructured":"Raterman HG, Bultink IEM, Lems WF. Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs. 2019;79(10):1065\u201387.","journal-title":"Drugs"},{"issue":"6","key":"1269_CR141","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1056\/NEJM199708073370603","volume":"337","author":"JD Adachi","year":"1997","unstructured":"Adachi JD, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337(6):382\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"1269_CR142","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339(5):292\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"1269_CR143","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44(1):202\u201311.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1269_CR144","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3899\/jrheum.081207","volume":"36","author":"SA Stoch","year":"2009","unstructured":"Stoch SA, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009;36(8):1705\u201314.","journal-title":"J Rheumatol"},{"issue":"11","key":"1269_CR145","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"S Cohen","year":"1999","unstructured":"Cohen S, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42(11):2309\u201318.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1269_CR146","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"DM Reid","year":"2000","unstructured":"Reid DM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15(6):1006\u201313.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1269_CR147","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000;67(4):277\u201385.","journal-title":"Calcif Tissue Int"},{"issue":"9671","key":"1269_CR148","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253\u201363.","journal-title":"Lancet"},{"issue":"10","key":"1269_CR149","first-page":"CD001347","volume":"10","author":"CS Allen","year":"2016","unstructured":"Allen CS, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10(10):CD001347.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1269_CR150","first-page":"dgz023","volume":"105","author":"L Ding","year":"2020","unstructured":"Ding L, et al. Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures. J Clin Endocrinol Metab. 2020;105(1):dgz023.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1269_CR151","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2017.8040","volume":"318","author":"KF Axelsson","year":"2017","unstructured":"Axelsson KF, et al. Association between alendronate use and hip fracture risk in older patients using oral prednisolone. JAMA. 2017;318(2):146\u201355.","journal-title":"JAMA"},{"issue":"3","key":"1269_CR152","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3318","volume":"33","author":"MA Amiche","year":"2018","unstructured":"Amiche MA, et al. Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J Bone Miner Res. 2018;33(3):419\u201329.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1269_CR153","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1210\/jc.2017-01912","volume":"103","author":"J Bergman","year":"2018","unstructured":"Bergman J, Nordstrom A, Nordstrom P. Alendronate use and the risk of nonvertebral fracture during glucocorticoid therapy: a retrospective cohort study. J Clin Endocrinol Metab. 2018;103(1):306\u201313.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1269_CR154","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00198-014-3022-9","volume":"26","author":"RA Overman","year":"2015","unstructured":"Overman RA, et al. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015;26(5):1515\u201324.","journal-title":"Osteoporos Int"},{"issue":"1","key":"1269_CR155","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bone.2011.01.003","volume":"49","author":"M Pazianas","year":"2011","unstructured":"Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49(1):103\u201310.","journal-title":"Bone"},{"issue":"5","key":"1269_CR156","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ki.2008.193","volume":"74","author":"S Boonen","year":"2008","unstructured":"Boonen S, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74(5):641\u20138.","journal-title":"Kidney Int"},{"issue":"2","key":"1269_CR157","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bone.2013.02.004","volume":"55","author":"B Ettinger","year":"2013","unstructured":"Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone. 2013;55(2):495\u2013500.","journal-title":"Bone"},{"issue":"8","key":"1269_CR158","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383(8):743\u201353.","journal-title":"N Engl J Med"},{"issue":"1","key":"1269_CR159","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","volume":"86","author":"J Schilcher","year":"2015","unstructured":"Schilcher J, et al. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100\u20137.","journal-title":"Acta Orthop"},{"issue":"11","key":"1269_CR160","doi-asserted-by":"publisher","first-page":"e2141","DOI":"10.1210\/clinem\/dgae023","volume":"109","author":"DC Bauer","year":"2024","unstructured":"Bauer DC, et al. Bisphosphonate use and risk of atypical femoral fractures: a Danish case-cohort study with blinded radiographic review. J Clin Endocrinol Metab. 2024;109(11):e2141\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1269_CR161","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","volume":"107","author":"AD Anastasilakis","year":"2022","unstructured":"Anastasilakis AD, et al. Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. J Clin Endocrinol Metab. 2022;107(5):1441\u201360.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1269_CR162","volume":"17","author":"M Sano","year":"2025","unstructured":"Sano M, et al. Prevalence of bisphosphonate and denosumab use in elderly care facilities: implications for the management of medication-related osteonecrosis of the jaw. Cureus. 2025;17(5):e83490.","journal-title":"Cureus."},{"issue":"6","key":"1269_CR163","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1269_CR164","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","volume":"71","author":"KG Saag","year":"2019","unstructured":"Saag KG, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial. Arthritis Rheumatol. 2019;71(7):1174\u201384.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1269_CR165","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/jbmr.4551","volume":"37","author":"P Geusens","year":"2022","unstructured":"Geusens P, et al. Effect of denosumab compared with risedronate on bone strength in patients initiating or continuing glucocorticoid treatment. J Bone Miner Res. 2022;37(6):1136\u201346.","journal-title":"J Bone Miner Res"},{"key":"1269_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115902","volume":"146","author":"CC Mok","year":"2021","unstructured":"Mok CC, et al. Denosumab versus alendronate in long-term glucocorticoid users: a 12-month randomized controlled trial. Bone. 2021;146:115902.","journal-title":"Bone"},{"issue":"6","key":"1269_CR167","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/art.39075","volume":"67","author":"JR Curtis","year":"2015","unstructured":"Curtis JR, et al. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol. 2015;67(6):1456\u201364.","journal-title":"Arthritis Rheumatol"},{"key":"1269_CR168","unstructured":"Tsourdi E, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020."},{"issue":"5","key":"1269_CR169","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","volume":"15","author":"NE Lane","year":"2000","unstructured":"Lane NE, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000;15(5):944\u201351.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"1269_CR170","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Investig. 1998;102(8):1627\u201333.","journal-title":"J Clin Investig"},{"issue":"1","key":"1269_CR171","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","volume":"14","author":"Q Rehman","year":"2003","unstructured":"Rehman Q, et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int. 2003;14(1):77\u201381.","journal-title":"Osteoporos Int"},{"issue":"20","key":"1269_CR172","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028\u201339.","journal-title":"N Engl J Med"},{"issue":"11","key":"1269_CR173","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346\u201355.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1269_CR174","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocd.2008.10.002","volume":"12","author":"BR Losada","year":"2009","unstructured":"Losada BR, et al. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. J Clin Densitom. 2009;12(1):63\u201370.","journal-title":"J Clin Densitom"},{"issue":"4","key":"1269_CR175","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.bone.2009.12.032","volume":"46","author":"AL Burshell","year":"2010","unstructured":"Burshell AL, et al. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone. 2010;46(4):935\u20139.","journal-title":"Bone"},{"issue":"1","key":"1269_CR176","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3899\/jrheum.090411","volume":"37","author":"JP Devogelaer","year":"2010","unstructured":"Devogelaer JP, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol. 2010;37(1):141\u20138.","journal-title":"J Rheumatol"},{"issue":"10","key":"1269_CR177","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1210\/jc.2002-020334","volume":"87","author":"JJ Body","year":"2002","unstructured":"Body JJ, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87(10):4528\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1269_CR178","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","volume":"20","author":"BL Langdahl","year":"2009","unstructured":"Langdahl BL, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009;20(12):2095\u2013104.","journal-title":"Osteoporos Int"},{"issue":"6","key":"1269_CR179","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jbmr.1870","volume":"28","author":"CC Gluer","year":"2013","unstructured":"Gluer CC, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355\u201368.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1269_CR180","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00774-020-01171-5","volume":"39","author":"I Tanaka","year":"2021","unstructured":"Tanaka I, et al. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. J Bone Miner Metab. 2021;39(3):446\u201355.","journal-title":"J Bone Miner Metab"},{"key":"1269_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100293","volume":"13","author":"Y Hirooka","year":"2020","unstructured":"Hirooka Y, et al. Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Bone Rep. 2020;13:100293.","journal-title":"Bone Rep"},{"key":"1269_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.753185","volume":"12","author":"Y Hirooka","year":"2021","unstructured":"Hirooka Y, et al. Four-year teriparatide followed by denosumab vs. continuous denosumab in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Front Endocrinol (Lausanne). 2021;12:753185.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1269_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267706","volume":"17","author":"ZM Liu","year":"2022","unstructured":"Liu ZM, et al. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: a meta-analysis and systematic review of randomized controlled trials. PLoS ONE. 2022;17(5):e0267706.","journal-title":"PLoS ONE"},{"key":"1269_CR184","doi-asserted-by":"publisher","first-page":"1391356","DOI":"10.3389\/fphar.2024.1391356","volume":"15","author":"MT Wen","year":"2024","unstructured":"Wen MT, et al. Indications and adverse events of teriparatide: based on FDA Adverse Event Reporting System (FAERS). Front Pharmacol. 2024;15:1391356.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1269_CR185","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1007\/s00198-012-1955-4","volume":"23","author":"D Michalska","year":"2012","unstructured":"Michalska D, et al. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Osteoporos Int. 2012;23(12):2885\u201391.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1269_CR186","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697\u2013706.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1269_CR187","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722\u201333.","journal-title":"JAMA"},{"issue":"1","key":"1269_CR188","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11657-019-0564-7","volume":"14","author":"EV McCloskey","year":"2019","unstructured":"McCloskey EV, et al. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos. 2019;14(1):15.","journal-title":"Arch Osteoporos"},{"issue":"8","key":"1269_CR189","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/jbmr.3163","volume":"32","author":"EV McCloskey","year":"2017","unstructured":"McCloskey EV, et al. The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE study. J Bone Miner Res. 2017;32(8):1625\u201331.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1269_CR190","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412\u201320.","journal-title":"N Engl J Med"},{"issue":"8","key":"1269_CR191","doi-asserted-by":"publisher","first-page":"e2778","DOI":"10.1210\/clinem\/dgae810","volume":"110","author":"M Kawazoe","year":"2025","unstructured":"Kawazoe M, et al. Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy. J Clin Endocrinol Metab. 2025;110(8):e2778\u201386.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1269_CR192","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00774-024-01531-5","volume":"42","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, et al. Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials. J Bone Miner Metab. 2024;42(5):492\u2013502.","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"1269_CR193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","volume":"33","author":"S Singh","year":"2022","unstructured":"Singh S, et al. A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int. 2022;33(1):1\u201312.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1269_CR194","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/mab.2019.0049","volume":"39","author":"G Mariscal","year":"2020","unstructured":"Mariscal G, et al. Safety of romosozumab in osteoporotic men and postmenopausal women: a meta-analysis and systematic review. Monoclonal Antibodies Immunodiagn Immunother. 2020;39(2):29\u201336.","journal-title":"Monoclonal Antibodies Immunodiagn Immunother"},{"issue":"11","key":"1269_CR195","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","volume":"39","author":"S Kaveh","year":"2020","unstructured":"Kaveh S, et al. Efficacy and safety of romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol. 2020;39(11):3261\u201376.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1269_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081660","volume":"10","author":"A Vestergaard Kvist","year":"2021","unstructured":"Vestergaard Kvist A, et al. Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med. 2021;10(8):1660.","journal-title":"J Clin Med"},{"issue":"4","key":"1269_CR197","first-page":"363","volume":"160","author":"THA Tan","year":"2024","unstructured":"Tan THA, et al. Assessment of fracture risk with FRAX and FRAXplus. Gac Med Mex. 2024;160(4):363\u201373.","journal-title":"Gac Med Mex"},{"issue":"2","key":"1269_CR198","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","volume":"42","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, et al. The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab. 2024;42(2):143\u201354.","journal-title":"J Bone Miner Metab"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01269-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01269-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01269-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:03:19Z","timestamp":1769702599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01269-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":198,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1269"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01269-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elena Tsourdi reports honoraria for lectures and advisory boards from Amgen, UCB, Alexion, and Ascendis and educational grants from UCB. Martina Rauner reports honoraria for lectures and advisory boards from Alexion, UCB, and Vifor Pharma. Hanna Taipaleenm\u00e4ki reports honoraria for lectures from UCB. Elizabeth M. Winter reports honoraria for lectures and advisory boards from Amgen, and\u00a0UCB. Ulrike Baschant has no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ET, UB, MR, HT, and EMW drafted the manuscript together. All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}